A Dexcom spokeswoman said there are already 20,000 Medicare patients in the pipeline with almost no advertisement of the policy change.
After hitting a few snags and finding a partner to create the bundle needed for Medicare shipping requirements, Dexcom is now shipping the Dexcom G5 to beneficiaries who meet criteria for coverage for continuous glucose monitoring (CGM).
A 2-step process over the past year allowed Medicare patients to gain access to CGM, after years of work by advocacy groups, physicians, patients, and members of Congress. First, FDA updated the Dexcom G5 approval to include dosing, which paved the way for CMS to add the Dexcom G5 to its schedule of durable medical equipment. Dexcom’s G5 is the only CGM system approved for therapeutic use, which means patients need the system to maintain glycemic control.
It wasn’t that easy at first. Dexcom had to find a partner in Ascensia, which provides the blood glucose monitoring system that beneficiaries will use twice a day to calibrate the CGM. Per Medicare rules, the products had to be shipped together. That agreement was reached in early July.
Demand among beneficiaries is so high that 20,000 Medicare patients are currently in the pipeline for CGM before Dexcom has done any major promotion of the change of Medicare policy, spokeswoman Julia Yuryev said in an e-mail to The American Journal of Managed Care®.
In total, 800,000 seniors are eligible for CGM, including virtually all Medicare beneficiaries with type 1 diabetes (T1D), and those with type 2 diabetes (T2D) who are on intensive insulin therapy and have been performing blood glucose tests at least 4 times a day.
Yuryev said Dexcom has hired and trained a dedicated team of Medicare sales and support staff for beneficiaries who are assisting existing Dexcom CGM patients, following by new patients in the order their requests were received.
To be eligible for reimbursement, Medicare requires specific documentation from physicians in patient medical records. The following must be documented:
Failure to meet the criteria mean Medicare will not pay for the Dexcom G5 or the supplies, giving patients a strong incentive to have good adherence.
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Commonwealth Fund Report Details Pervasive Racial and Ethnic Disparities in US Health Care, Outcomes
April 18th 2024Using 25 health system performance indicators, the Commonwealth Fund 2024 State Health Disparities Report evaluated racial and ethnic disparities in health care and health outcomes both within and across US states and highlighted the urgent need for equitable health care policies and practices in the US.
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
The Biden administration recently launched the Global Health Security Strategy, a new effort to combat the spread of infectious diseases; lawmakers zeroed in on the risks of massive consolidation in health care during the first congressional hearing on the Change Healthcare hack; the FDA recently announced the recall of a pair of heart devices linked to numerous deaths and injuries.
Read More